Menu

ISTOCK, SELVANEGRA

Alzheimer’s Drug Slows Symptoms, Reduces Plaques

In a clinical trial, patients on the highest injected dose had 30 percent less cognitive decline over time than people on a placebo.

Jul 26, 2018
Kerry Grens

An Alzheimer’s drug slows the rate of cognitive decline while reducing the amount of plaques in patients’ brains, according to the results of a clinical trial reported yesterday (June 25) at the Alzheimer’s Association International Conference in Chicago. Compared to participants on a placebo, those who received the highest dose of the injected medicine had a 30 percent slower progression in symptoms.

“If you could really slow decline by 30 percent for people who are still normal or very mildly impaired, that would be clinically important,” Reisa Sperling, director of the Center for Alzheimer Research and Treatment at Brigham and Women’s Hospital in Boston who was not involved in the study, tells The New York Times.

The study included more than 800 people with mild cognitive decline, and 161 received the highest of five doses, injected twice weekly for 18 months. The medicine, a monoclonal antibody called BAN2401, targets amyloid in the brain. Four out of five on the highest dose went from having amyloid levels associated with dementia to levels below the pathologic threshold.  

Despite excitement from the Alzheimer’s field over the results, investors were discouraged. At lower doses of the drug, patients’ performance was no better than placebo, and shares of the drug’s maker, Eisai, dropped by as much as 21 percent yesterday, Reuters reports.

STAT News notes that the cognitive test used in the trial has never formed the basis of a drug approval by the US Food and Drug Administration.

“I’ll remain cautiously optimistic,” Ronald Petersen, director of Mayo Clinic Alzheimer’s Disease Research Center who consults for Eisai’s partner Biogen, tells STAT. “I think the data are intriguing. The effect sizes sound reasonable, the drug seems safe, and on the biological side of it, the drug seems to be working.”

September 2018

The Muscle Issue

The dynamic tissue reveals its secrets

Marketplace

Sponsored Product Updates

Horizon Discovery introduces Myeloid DNA Reference Standard to support genetic testing of leukemia

Horizon Discovery introduces Myeloid DNA Reference Standard to support genetic testing of leukemia

Horizon Discovery Group plc, a global leader in gene editing and gene modulation technologies, today announced the launch of its Myeloid DNA Reference Standard. The first-to-market large cell-line derived myeloid cancer reference standard designed enables faster, more reliable and more cost-effective assay validation, to support the market in bringing routine testing into practice.

StemExpress LeukopakâNow Available in Frozen Format

StemExpress LeukopakâNow Available in Frozen Format

StemExpress, a Folsom, California based leading supplier of human biospecimens, announces the release of frozen Peripheral Blood Leukopaks. Leukopaks provide an enriched source of peripheral blood mononuclear cells (PBMCs) with low granulocyte and red blood cells that can be used in a variety of downstream cell-based applications.

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

Vector Laboratories, a leader in the development and manufacture of labeling and detection reagents for biomedical research, introduces VECTASHIELD® Vibrance™ – antifade mounting media that delivers significant improvements to the immunofluorescence workflow.

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Download this white paper from Bertin Technologies to learn how to extract and analyze lipid samples from various models!